Biology of HLA class I associated inflammatory diseases

IF 4.5 2区医学 Q1 RHEUMATOLOGY

Best Practice & Research in Clinical Rheumatology Pub Date : 2024-05-01 DOI:10.1016/j.berh.2024.101977

Ali Bordbar , Olivier Manches , Johannes Nowatzky

引用次数: 0

Abstract

Human leukocyte antigen (HLA) class I association is a well-established feature of common and uncommon inflammatory diseases, but it is unknown whether it impacts the pathogenesis of these disorders. The “arthritogenic peptide” hypothesis proposed initially for HLA-B27-associated ankylosing spondylitis (AS) seems the most intuitive to serve as a model for other HLA class I-associated diseases, but evidence supporting it has been scarce. Recent technological advances and the discovery of epistatic relationships between disease-associated HLA class I and endoplasmic reticulum aminopeptidase (ERAP) coding variants have led to the generation of new data and conceptual approaches to the problem requiring its re-examination. Continued success in these endeavors holds promise to resolve a Gordian Knot in human immunobiology. It may ultimately benefit patients by enabling the development of new therapies and precision tools for assessing disease risk and predicting treatment responses.

查看原文本刊更多论文

与 HLA I 类相关的炎症疾病生物学。

人类白细胞抗原（HLA）Ⅰ类关联是常见和不常见炎症性疾病的一个公认特征，但它是否会影响这些疾病的发病机制尚不清楚。最初针对与 HLA-B27 相关的强直性脊柱炎（AS）提出的 "关节炎原肽 "假说似乎最直观，可作为其他 HLA I 类相关疾病的模型，但支持这一假说的证据一直很少。最近的技术进步以及与疾病相关的 HLA I 类和内质网氨肽酶（ERAP）编码变体之间表观关系的发现，产生了新的数据和概念方法，需要对这一问题进行重新研究。这些努力不断取得成功，有望解决人类免疫生物学中的一个死结。通过开发新的疗法和用于评估疾病风险和预测治疗反应的精确工具，最终可能使患者受益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Best Practice & Research in Clinical Rheumatology 医学-风湿病学

CiteScore

9.40

自引率

0.00%

发文量

审稿时长

27 days

期刊介绍： Evidence-based updates of best clinical practice across the spectrum of musculoskeletal conditions. Best Practice & Research: Clinical Rheumatology keeps the clinician or trainee informed of the latest developments and current recommended practice in the rapidly advancing fields of musculoskeletal conditions and science. The series provides a continuous update of current clinical practice. It is a topical serial publication that covers the spectrum of musculoskeletal conditions in a 4-year cycle. Each topic-based issue contains around 200 pages of practical, evidence-based review articles, which integrate the results from the latest original research with current clinical practice and thinking to provide a continuous update. Each issue follows a problem-orientated approach that focuses on the key questions to be addressed, clearly defining what is known and not known. The review articles seek to address the clinical issues of diagnosis, treatment and patient management. Management is described in practical terms so that it can be applied to the individual patient. The serial is aimed at the physician in both practice and training.